HIMS Dips 55.8% in 3 Months: Should You Still Hold the Stock or Sell?

Core Insights - Hims & Hers Health, Inc. (HIMS) has faced significant short-term losses, with its stock down 55.8% over the past three months, compared to a 31.4% decline in the industry and gains of 0.4% and 2% in the sector and S&P 500, respectively [1][10]. Financial Performance - The company reported strong top-line growth in Q3 2025, driven by subscriber growth and increased average monthly online revenue per subscriber, but experienced disappointing bottom-line results with declining margins [3][15]. - HIMS expects Q4 2025 revenues between $605 million and $625 million, reflecting a year-over-year increase of 26%-30%, and full-year revenues between $2.335 billion and $2.355 billion, representing growth of 58%-59% from 2024 [9]. - The Zacks Consensus Estimate for Q4 2025 revenues is $620.4 million, with earnings per share estimated at 4 cents [9]. Regulatory and Legal Challenges - HIMS faces heightened regulatory scrutiny from the FDA regarding compounded GLP-1 drugs, which could impact its operations in the weight-loss sector [12]. - A lawsuit from Novo Nordisk alleges patent infringement related to HIMS' compounded semaglutide products, introducing potential financial liabilities and uncertainty [13]. - The company’s reliance on complex compounding regulations increases compliance risks, particularly in its growth categories [14]. Competitive Landscape - HIMS operates in a highly competitive market, facing challenges from traditional healthcare providers and other telehealth platforms, which could pressure pricing and customer acquisition [16]. - Despite strong revenue growth, profitability trends have softened, with gross margins declining due to cost pressures [15]. Strategic Developments - HIMS launched Galleri, a multi-cancer early detection blood test, in collaboration with GRAIL, enhancing access to proactive care [2]. - The company is expanding its addressable market by introducing new specialties, including low testosterone treatments and menopause care, which could deepen engagement with subscribers [17][24]. - HIMS is shifting towards proactive health insights through comprehensive lab testing, which may enhance cross-selling opportunities and strengthen its subscription model [18]. Valuation Metrics - HIMS' forward 12-month price-to-sales (P/S) ratio is 1.4X, lower than the industry average of 3.6X and its three-year median of 2.6X [19]. - Comparatively, Teladoc Health and Tempus AI have forward P/S ratios of 0.3X and 6.2X, respectively [21]. Estimate Movements - Estimates for HIMS' 2026 earnings per share have decreased by 6.8% to 55 cents in the past 60 days [22].